SPPI: Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS(TM) (eflapegrastim), a Novel Long-Acting GCSF

New alert via PocketInfo for SPPI:

Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS(TM) (eflapegrastim), a Novel Long-Acting GCSF

Press Releases: http://investor.spectrumpharm.com/releases.cfm
SEC Filings: http://investor.spectrumpharm.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8